Benitec Biopharma Inc. (BNTC) Form 8-K — Sep 14, 2026
Benitec Biopharma reported fiscal year 2026 results (year ended June 30, 2026), posting a net loss of $45.5 million, or $0.98 per basic and diluted share, versus a $37.9 million loss, or $1.05 per share, the prior year. Total operating expenses rose to $51.2 million from $41.8 million, driven by higher R&D spending and share-based compensation. On the clinical side, all six Cohort 1 low-dose BB-301 patients have completed the full 12-month post-treatment follow-up, and Cohort 2 (high dose) is fully enrolled with all three patients safely treated. Clinically meaningful improvements in swallowing function were observed alongside a favorable safety profile.
Key figures
- Eps
- -$0.98 basic and diluted (FY2026) vs -$1.05 (FY2025)
- Net Income
- -$45.5 million (FY2026) vs -$37.9 million (FY2025)
- Total Assets
- $182.6 million
- Cash Position
- $180.0 million ($179,972 thousand) as of June 30, 2026 vs $97.7 million a year earlier
- Ga Expenses
- $27.8 million (FY2026) vs $23.4 million (FY2025)
- Rnd Expenses
- $23.4 million (FY2026) vs $18.3 million (FY2025)
- Total Liabilities
- $5.6 million
- Interest Income Net
- $5.6 million
- Pivotal Trial Start
- mid-2027 (planned)
- Shares Outstanding
- 34416834
- Stockholders Equity
- $177.0 million
- Weighted Average Shares
- 46558162
- Total Operating Expenses
- $51.2 million (FY2026) vs $41.8 million (FY2025)
- Prior Year Shares Outstanding
- 26250469
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.